Inhibikase Therapeutics Statistics
Share Statistics
Inhibikase Therapeutics has 67.19M shares outstanding. The number of shares has increased by 937.43% in one year.
| Shares Outstanding | 67.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 800.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 51.26M |
| Failed to Deliver (FTD) Shares | 18.51K |
| FTD / Avg. Volume | 2.79% |
Short Selling Information
The latest short interest is 187.95K, so 0.28% of the outstanding shares have been sold short.
| Short Interest | 187.95K |
| Short % of Shares Out | 0.28% |
| Short % of Float | 0.37% |
| Short Ratio (days to cover) | 0.17 |
Valuation Ratios
The PE ratio is -0.36 and the forward PE ratio is -11.56.
| PE Ratio | -0.36 |
| Forward PE | -11.56 |
| PS Ratio | 26 |
| Forward PS | 26 |
| PB Ratio | 0.62 |
| P/FCF Ratio | -0.37 |
| PEG Ratio | n/a |
Enterprise Valuation
Inhibikase Therapeutics Inc. has an Enterprise Value (EV) of -1.77M.
| EV / Earnings | 0.09 |
| EV / Sales | -6.8 |
| EV / EBITDA | 0.09 |
| EV / EBIT | 0.09 |
| EV / FCF | 0.1 |
Financial Position
The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.13 |
| Quick Ratio | 4.13 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3.36 |
| Cash Flow / Debt | -47.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.73% and return on capital (ROIC) is -173.19%.
| Return on Equity (ROE) | -1.73% |
| Return on Assets (ROA) | -1.31% |
| Return on Capital (ROIC) | -173.19% |
| Revenue Per Employee | 32.56K |
| Profits Per Employee | -2.38M |
| Employee Count | 8 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 149.25% in the last 52 weeks. The beta is 1.12, so Inhibikase Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | 149.25% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 58.06 |
| Average Volume (20 Days) | 662.72K |
Income Statement
In the last 12 months, Inhibikase Therapeutics had revenue of 260.50K and earned -19.03M in profits. Earnings per share was -3.57.
| Revenue | 260.50K |
| Gross Profit | -13.36M |
| Operating Income | -20.09M |
| Net Income | -19.03M |
| EBITDA | -19.91M |
| EBIT | -20.09M |
| Earnings Per Share (EPS) | -3.57 |
Balance Sheet
The company has 9.17M in cash and 622.00K in debt, giving a net cash position of 8.54M.
| Cash & Cash Equivalents | 9.17M |
| Total Debt | 622.00K |
| Net Cash | 8.54M |
| Retained Earnings | -66.90M |
| Total Assets | 4.38M |
| Working Capital | -717.36K |
Cash Flow
In the last 12 months, operating cash flow was -18.09M and capital expenditures -14.24K, giving a free cash flow of -18.10M.
| Operating Cash Flow | -18.09M |
| Capital Expenditures | -14.24K |
| Free Cash Flow | -18.10M |
| FCF Per Share | -3.39 |
Margins
Gross margin is -512.78K%, with operating and profit margins of -771.20K% and -730.48K%.
| Gross Margin | -512.78K% |
| Operating Margin | -771.20K% |
| Pretax Margin | -730.48K% |
| Profit Margin | -730.48K% |
| EBITDA Margin | -7.64K% |
| EBIT Margin | -7.71K% |
| FCF Margin | -6.95K% |
Dividends & Yields
IKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -106.89% |
| FCF Yield | -8.06% |
Analyst Forecast
The average price target for IKT is $6.5, which is 94.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 94.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 30, 2023. It was a backward split with a ratio of 1:6.
| Last Split Date | Jun 30, 2023 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -17.33 |
| Piotroski F-Score | 1 |